Medistep Healthcare Ltd
Incorporated in June 2023, Medistep Healthcare Ltd manufactures and trades healthcare and personal care products.[1]
- Market Cap ₹ 25.6 Cr.
- Current Price ₹ 18.0
- High / Low ₹ 53.0 / 16.5
- Stock P/E 4.28
- Book Value ₹ 26.6
- Dividend Yield 0.00 %
- ROCE 27.2 %
- ROE 21.9 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.68 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 203 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Personal Products Personal Care
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 9m | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 31.60 | 49.65 | 70.83 | |
| 27.64 | 44.04 | 62.58 | |
| Operating Profit | 3.96 | 5.61 | 8.25 |
| OPM % | 12.53% | 11.30% | 11.65% |
| 0.01 | -0.00 | 0.02 | |
| Interest | 0.06 | 0.04 | 0.25 |
| Depreciation | 0.02 | 0.03 | 0.03 |
| Profit before tax | 3.89 | 5.54 | 7.99 |
| Tax % | 25.19% | 25.09% | 25.16% |
| 2.91 | 4.14 | 5.98 | |
| EPS in Rs | 5.94 | 3.96 | 4.21 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 24% |
| Last Year: | 22% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 4.90 | 10.47 | 14.21 |
| Reserves | 6.79 | 6.37 | 23.62 |
| 0.33 | 0.64 | 5.18 | |
| 2.93 | 5.51 | 7.29 | |
| Total Liabilities | 14.95 | 22.99 | 50.30 |
| 0.15 | 0.12 | 0.12 | |
| CWIP | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 |
| 14.80 | 22.87 | 50.18 | |
| Total Assets | 14.95 | 22.99 | 50.30 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -7.11 | 0.02 | -19.48 | |
| -0.15 | -0.00 | -0.01 | |
| 7.24 | 1.28 | 18.79 | |
| Net Cash Flow | -0.02 | 1.30 | -0.70 |
| Free Cash Flow | -7.26 | 0.02 | -19.49 |
| CFO/OP | -180% | 1% | -224% |
Ratios
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 158.82 | 147.84 | 202.98 |
| Inventory Days | 12.41 | 9.23 | 36.49 |
| Days Payable | 18.81 | 20.55 | 21.55 |
| Cash Conversion Cycle | 152.42 | 136.52 | 217.92 |
| Working Capital Days | 133.76 | 113.29 | 191.18 |
| ROCE % | 37.83% | 27.25% |
Insights
In beta| Jul 2025 | |
|---|---|
| Number of Distributors/Stockists Number |
|
Extracted by Screener AI
Documents
Announcements
-
Outcome of Board Meeting
30 May 2026 - Board approved standalone audited results for half-year and year ended 31 March 2026; auditor gave unmodified opinion.
-
Disclosure under SEBI Takeover Regulations
20 May 2026 - GIRDHARILAL PRAJAPAT has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
-
Structural Digital Database
30 April 2026 - Submitted SDD compliance certificate for year ended 31 March 2026; no non-compliance reported.
-
Disclosure under SEBI Takeover Regulations
23 April 2026 - GIRDHARILAL PRAJAPAT has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
15 April 2026 - Company confirms corporate governance report not applicable for FY and quarter ended 31 March 2026.
Business Overview:[1]
MHL is engaged in the business of manufacturing of sanitary pads and energy powder, as well as the
trading and distribution of a wide range of healthcare products comprising pharmaceutical
formulations, nutraceutical products, intimate care products, and surgical supplies.